Literature DB >> 31585276

Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.

Yu Deng1, Tao Wu1, Shao-Qin Zhai1, Cheng-Hong Li2.   

Abstract

Toxoplasma gondii severely threaten the health of immunocompromised patients and pregnant women as this parasite can cause several disease, including brain and eye disease. Current treatment for toxoplasmosis commonly have high cytotoxic side effects on host and require long durations ranging from one week to more than one year. The regiments lack efficacy to eradicate T. gondii tissue cysts to cure chromic infection results in the needs for long treatment and relapsing disease. In addition, there has not been approved drugs for treating the pregnant women infected by T. gondii. Moreover, Toxoplasma vaccine researches face a wide variety of challenges. Developing high efficient and low toxic agents against T. gondii is urgent and important. Over the last decade, tremendous progress have been made in identifying and developing novel compounds for the treatment of toxoplasmosis. This review summarized and discussed recent advances between 2009 and 2019 in exploring effective agents against T. gondii from five aspects of drug discovery.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-parasitic drug; Screening; Structure activity relationship; Synthesis; Toxoplasma gondii

Mesh:

Substances:

Year:  2019        PMID: 31585276     DOI: 10.1016/j.ejmech.2019.111711

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Anti-Toxoplasma gondii Effects of a Novel Spider Peptide XYP1 In Vitro and In Vivo.

Authors:  Yuan Liu; Yaqin Tang; Xing Tang; Mengqi Wu; Shengjie Hou; Xiaohua Liu; Jing Li; Meichun Deng; Shuaiqin Huang; Liping Jiang
Journal:  Biomedicines       Date:  2021-08-01

2.  Discovery and Optimization of Triazine Nitrile Inhibitors of Toxoplasma gondii Cathepsin L for the Potential Treatment of Chronic Toxoplasmosis in the CNS.

Authors:  Jeffery D Zwicker; David Smith; Alfredo J Guerra; Jacob R Hitchens; Nicole Haug; Steve Vander Roest; Pil Lee; Bo Wen; Duxin Sun; Lu Wang; Richard F Keep; Jianming Xiang; Vern B Carruthers; Scott D Larsen
Journal:  ACS Chem Neurosci       Date:  2020-02-18       Impact factor: 4.418

3.  1,3,4-Thiadiazoles Effectively Inhibit Proliferation of Toxoplasma gondii.

Authors:  Lidia Węglińska; Adrian Bekier; Katarzyna Dzitko; Barbara Pacholczyk-Sienicka; Łukasz Albrecht; Tomasz Plech; Piotr Paneth; Agata Paneth
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 4.  Catastrophic consequences: can the feline parasite Toxoplasma gondii prompt the purrfect neuroinflammatory storm following traumatic brain injury?

Authors:  Tamara L Baker; Mujun Sun; Bridgette D Semple; Shiraz Tyebji; Christopher J Tonkin; Richelle Mychasiuk; Sandy R Shultz
Journal:  J Neuroinflammation       Date:  2020-07-25       Impact factor: 8.322

5.  Toxoplasma TgAtg8-TgAtg3 Interaction Primarily Contributes to Apicoplast Inheritance and Parasite Growth in Tachyzoite.

Authors:  Linyan Cheng; Yuan Tian; Yan Wang; Tingting Wang; Yinning Yao; Helin Yu; Xiaozi Zheng; Mimi Wu; Wei Zhao; Qianqian Hua; Xin Hu; Feng Tan
Journal:  Microbiol Spectr       Date:  2022-02-23

6.  Investigation of urine metabolome of BALB/c mouse infected with an avirulent strain of Toxoplasma gondii.

Authors:  Chun-Xue Zhou; Ling-Yu Li; Cui-Qin Huang; Xu-Dong Guo; Xu-Dian An; Fang-Fang Luo; Wei Cong
Journal:  Parasit Vectors       Date:  2022-07-29       Impact factor: 4.047

7.  Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.

Authors:  Shuxian Liu; Mimi Wu; Qianqian Hua; Daiqiang Lu; Yuan Tian; Helin Yu; Linyan Cheng; Yinqi Chen; Jiaxin Cao; Xin Hu; Feng Tan
Journal:  Parasit Vectors       Date:  2020-05-11       Impact factor: 3.876

Review 8.  Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis-A Short Bridge between Two Distant Illnesses.

Authors:  Alina Secrieru; Inês C C Costa; Paul M O'Neill; Maria L S Cristiano
Journal:  Molecules       Date:  2020-03-30       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.